Nivolumab for CNS relapsed refractory primary mediastinal B-cell lymphoma: case report and review of the literature-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nivolumab for CNS relapsed refractory primary mediastinal B-cell lymphoma: case report and review of the literature

Published:2024-09-03 Issue: Volume: Page:1-5
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Shaulov Adir¹^ORCID,Gross Even-Zohar Noa¹,Aumann Shlomzion¹,Haran Arnon¹^ORCID,Linetsky Eduard²

Affiliation:

1. Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

2. Department of Neuro-oncology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2396043

Reference32 articles.

1. How I treat primary mediastinal B-cell lymphoma

2. Biology and therapy of primary mediastinal B‐cell lymphoma: current status and future directions

3. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab

4. Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B‐cell lymphoma in the rituximab era

5. How I treat secondary CNS involvement by aggressive lymphomas

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP